Vitamin C for COVID-19 : A living systematic review
OBJECTIVE: This living systematic review aims to provide a timely, rigorous, and continuously updated summary of the available evidence on the role of vitamin C in treating patients with COVID-19.
DATA SOURCES: We conducted searches in PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature, and in a centralized repository in L·OVE (Living OVerview of Evidence). In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it comprises and has been customized to group all COVID-19 evidence in one place. All the searches covered the period until April 29, 2020 (one day before submission).
STUDY SELECTION AND METHODS: We adapted an already published standard protocol for multiple parallel systematic reviews. We searched for randomized trials evaluating the effect, in patients with COVID-19, of vitamin C versus placebo or no treatment. Anticipating the lack of randomized trials directly addressing this question, we also searched for trials evaluating MERS-CoV and SARS-CoV, and non-randomized studies in COVID-19. Two reviewers independently screened each study for eligibility. A living, web-based version of this review will be openly available during the COVID-19 pandemic, and we will resubmit it to the journal whenever there are substantial updates.
RESULTS: We screened 95 records, but no study was considered eligible. We identified 20 ongoing studies, including 13 randomized trials evaluating vitamin C in COVID-19.
CONCLUSIONS: We did not find any studies that met our inclusion criteria, and hence there is no evidence to support or refute the use of vitamin C in the treatment of patients with COVID-19. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon.
PROSPERO REGISTRATION NUMBER: CRD42020181216.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Medwave - 20(2020), 6 vom: 28. Juli, Seite e7978 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Vitamin C for COVID-19: A living systematic review |
|---|
| Beteiligte Personen: |
Baladia, Eduard [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ascorbic Acid |
|---|
| Anmerkungen: |
Date Completed 12.08.2020 Date Revised 16.04.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5867/medwave.2020.06.7978 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313350140 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313350140 | ||
| 003 | DE-627 | ||
| 005 | 20231225150403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5867/medwave.2020.06.7978 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1044.xml |
| 035 | |a (DE-627)NLM313350140 | ||
| 035 | |a (NLM)32759894 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baladia, Eduard |e verfasserin |0 (orcid)0000-0002-8123-8736 |4 aut | |
| 245 | 1 | 0 | |a Vitamin C for COVID-19 |b A living systematic review |
| 246 | 3 | 3 | |a Vitamin C for COVID-19: A living systematic review |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2020 | ||
| 500 | |a Date Revised 16.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: This living systematic review aims to provide a timely, rigorous, and continuously updated summary of the available evidence on the role of vitamin C in treating patients with COVID-19 | ||
| 520 | |a DATA SOURCES: We conducted searches in PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature, and in a centralized repository in L·OVE (Living OVerview of Evidence). In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it comprises and has been customized to group all COVID-19 evidence in one place. All the searches covered the period until April 29, 2020 (one day before submission) | ||
| 520 | |a STUDY SELECTION AND METHODS: We adapted an already published standard protocol for multiple parallel systematic reviews. We searched for randomized trials evaluating the effect, in patients with COVID-19, of vitamin C versus placebo or no treatment. Anticipating the lack of randomized trials directly addressing this question, we also searched for trials evaluating MERS-CoV and SARS-CoV, and non-randomized studies in COVID-19. Two reviewers independently screened each study for eligibility. A living, web-based version of this review will be openly available during the COVID-19 pandemic, and we will resubmit it to the journal whenever there are substantial updates | ||
| 520 | |a RESULTS: We screened 95 records, but no study was considered eligible. We identified 20 ongoing studies, including 13 randomized trials evaluating vitamin C in COVID-19 | ||
| 520 | |a CONCLUSIONS: We did not find any studies that met our inclusion criteria, and hence there is no evidence to support or refute the use of vitamin C in the treatment of patients with COVID-19. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon | ||
| 520 | |a PROSPERO REGISTRATION NUMBER: CRD42020181216 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Ascorbic Acid | |
| 650 | 4 | |a Coronavirus Infections | |
| 650 | 4 | |a Coronavirus disease | |
| 650 | 4 | |a Severe Acute Respiratory Syndrome Coronavirus 2 | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Vitamin C | |
| 650 | 4 | |a COVID-19 | |
| 650 | 7 | |a Vitamins |2 NLM | |
| 650 | 7 | |a Ascorbic Acid |2 NLM | |
| 650 | 7 | |a PQ6CK8PD0R |2 NLM | |
| 700 | 1 | |a Pizarro, Ana Beatriz |e verfasserin |0 (orcid)0000-0003-4089-454X |4 aut | |
| 700 | 1 | |a Ortiz-Muñoz, Luis |e verfasserin |0 (orcid)0000-0001-6449-2153 |4 aut | |
| 700 | 1 | |a Rada, Gabriel |e verfasserin |0 (orcid)0000-0003-2435-0710 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medwave |d 2014 |g 20(2020), 6 vom: 28. Juli, Seite e7978 |w (DE-627)NLM241622328 |x 0717-6384 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:6 |g day:28 |g month:07 |g pages:e7978 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5867/medwave.2020.06.7978 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 6 |b 28 |c 07 |h e7978 | ||